Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | +4.55% | +9.52% |
31/05 | EARNINGS AND TRADING: CT UK High Income tops benchmark, ups dividend | AN |
17/04 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 12.08M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics Plc
- BiVictriX Therapeutics Appoints New CFO